Zymeworks (NASDAQ:ZYME) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Zymeworks (NASDAQ:ZYME) from a strong-buy rating to a buy rating in a report released on Sunday.

Several other equities analysts have also recently commented on ZYME. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, October 8th. HC Wainwright raised shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Finally, B. Riley raised shares of Zymeworks to a “strong-buy” rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zymeworks has a consensus rating of “Buy”.

Zymeworks Trading Down 2.1%

NASDAQ:ZYME opened at $17.93 on Friday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $19.50. The firm has a 50-day moving average price of $15.97. The stock has a market cap of $1.35 billion, a PE ratio of -18.48 and a beta of 1.51.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings results on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. Zymeworks had a negative return on equity of 21.59% and a negative net margin of 59.96%.The company had revenue of $4.40 million for the quarter.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.